Snake venom enzyme could boost stroke recovery in rare brain clot study
NCT ID NCT07352358
First seen Jan 26, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This study tests whether adding batroxobin, a snake venom enzyme that dissolves clots, to standard blood thinners helps people with acute cerebral venous thrombosis (a rare stroke caused by a clot in a brain vein). Seventy-two adults will be randomly assigned to receive either standard anticoagulation alone or anticoagulation plus batroxobin. The main goal is to see if more patients achieve complete clot clearance within 7 days with the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL VENOUS THROMBOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
batroxobin (a snake venom enzyme that breaks down blood clots) plus standard anticoagulants (low-molecular-weight heparin, warfarin, rivaroxaban, or dabigatran)
What this could lead to
If successful, this combination could speed up clot removal and improve recovery for people with cerebral venous thrombosis, a rare type of stroke.
What could go wrong
This is a small, early-phase 4 trial with only 72 participants, so results may not apply broadly. Batroxobin can increase bleeding risk, especially when combined with blood thinners.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.